A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration‐resistant metastatic prostate cancer
| العنوان: | A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration‐resistant metastatic prostate cancer |
|---|---|
| المؤلفون: | Nielka P. van Erp, Guillemette E. Benoist, Niven Mehra, Maarten J. van der Doelen, Rob ter Heine |
| المصدر: | British Journal of Clinical Pharmacology, 84, 5, pp. 1064-1067 British Journal of Clinical Pharmacology, 84, 1064-1067 |
| بيانات النشر: | John Wiley and Sons Inc., 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Case Reports, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], 030226 pharmacology & pharmacy, 03 medical and health sciences, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, All institutes and research themes of the Radboud University Medical Center, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, Pharmacology (medical), Adverse effect, Pharmacology, medicine.diagnostic_test, business.industry, Abiraterone acetate, Carbamazepine, medicine.disease, Discontinuation, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], chemistry, Therapeutic drug monitoring, 030220 oncology & carcinogenesis, Concomitant, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Prednisolone, business, medicine.drug |
| الوصف: | Adverse event Decreased abiraterone exposure after introducing carbamazepine. Drugs implicated Abiraterone acetate and carbamazepine. The patient A 65-year-old man with metastatic castration resistant prostate cancer, was treated with abiraterone acetate and prednisolone, and received concomitant carbamazepine for treatment of facial neuropathy. Evidence that links the drug to the event The interaction was confirmed by a decrease in abiraterone exposure >2-fold (area-under-the-curve and trough levels). After discontinuation of carbamazepine therapy, the abiraterone exposure normalized. No alternative causes were found that explain the decrease in abiraterone exposure. Mechanism Induction of CYP3A and potentially phase I metabolism (SULT2A1) by carbamazepine. Implications for therapy Clinicians and pharmacists should be aware of this clinically relevant interaction. The national drug-drug interaction checker does not warn for this interaction, whereas both the Lexicomp® and Micromedex® advice to avoid if possible or to increase the abiraterone dose frequency to twice daily. Carbamazepine should not be combined with abiraterone to avoid underexposure and suboptimal therapy. Therapeutic drug monitoring of abiraterone is useful to guide therapy when drug-drug interactions cannot be avoided. |
| اللغة: | English |
| تدمد: | 0306-5251 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02e165996a1e89bbf3360ebdd98fed82Test https://europepmc.org/articles/PMC5903233Test/ |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....02e165996a1e89bbf3360ebdd98fed82 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 03065251 |
|---|